Psychedelic Research
Organization of ZurichStudent association
in Zürich
We organise free public talks in Zürich about psychedelic research, therapy, and society. Run by students, open to everyone. Watch past talks online.
Next talk · Set, Setting, and Statute: A Legal Journey through Psychedelic Prohibition, Human Rights, and the Rule of Law
Our upcoming talk
20.10.26
Sebastian William Foster
Tuesday, October 20, 2026
18:30
Universität Zürich · HAH-E-03, Häldeliweg 2, 8044 Zürich
Also this autumn
About the talk
Title and abstract to be announced.
Time and venue
Venue to be announced!
Save the date · time and venue to follow.
About the talk
A public lecture in English with Prof. Dr. Linda Simmler on psychedelics and their role in neuroplasticity. A 45-minute talk followed by 15 minutes of audience questions. Free admission. Full abstract to follow.
Time and venue
18:30 · Universität Zürich · HAH-E-03, Häldeliweg 2, 8044 Zürich
About the talk
How does a promising psychedelic compound become a treatment patients can benefit from? This lecture offers a behind-the-scenes perspective on psychedelic drug development, exploring the scientific questions and practical decisions that connect laboratory discoveries with clinical care. Drawing on his translational research with DMT-based formulations, Milan Scheidegger discusses the interplay between pharmacology and therapeutic context, alongside key clinical and regulatory challenges. At the intersection of neuroscience, psychiatry and biotechnology, the talk examines the opportunities and open questions on the path towards approved psychedelic treatments.
Time and venue
18:30 · Universität Zürich · HAH-E-03, Häldeliweg 2, 8044 Zürich
From the archive
From Renaissance to ConfluenceDr. Adana Omágua-Kambeba · 1 h 5 minHow can psychedelic science build more reciprocal relationships with the Indigenous communities whose knowledge has helped shape the field? Through the concept of Cosmic Diplomacy, Adana Omágua-Kambeba explores dialogue between Indigenous and Western sciences grounded in respect and intercultural collaboration. The talk considers partnerships among Indigenous communities, universities, health professionals, and the pharmaceutical industry. Confluence invites different knowledge traditions to meet while retaining their distinct perspectives, with shared responsibility for people, territories, and the future of health.
Dr. Adana Omágua-Kambeba is a physician and knowledge keeper of the Omágua-Kambeba people of the Brazilian Amazon. She studied medicine at the Universidade Federal de Minas Gerais. Her work connects Indigenous medicine, Western science, and intercultural dialogue, approaching health through relationships with community, territory, plants, and ancestors.
Psychedelics and CreativityDila Suay · 42 minDila Suay explores the relationship between psychedelics and creativity, from their history in creative expression to controlled laboratory research. Drawing on studies with an ayahuasca-inspired DMT/harmine formulation, she considers divergent and convergent thinking, artistic expression and the lived experience of creating. The talk connects experimental neuroscience with questions about imagination and perception.
Dila Suay is a translational neuroscientist with a background in molecular biology, genetics and bioengineering. She completed her PhD at IMT School for Advanced Studies Lucca in collaboration with the University of Zurich, using EEG and behavioural methods to study psychedelic effects on creativity, perception and self-related processing.
Death and Sacred KnowledgeWilliam Richards · 1 h 30 minBill Richards reflects on altered states of consciousness, the history of psychedelic research and care at the end of life. Drawing on decades of clinical work and personal recollections, he considers how these experiences may relate to meaning, spiritual life and psychological distress in palliative care.
William “Bill” Richards is a clinical psychologist and a longstanding researcher in psychedelic-assisted psychotherapy. His work includes early studies in Maryland and the revival of psilocybin research at Johns Hopkins. He is the author of Sacred Knowledge: Psychedelics and Religious Experiences.
Transdiagnostic Effects and Mechanisms of PAT: Clinical Insights from Our Patient CohortSusanne Prinz · 1 h 5 minSusanne Prinz asks how psychedelic-assisted therapy may change the ways people relate to themselves, their emotions and others across diagnostic categories. She discusses connectedness, emotional access, meaning-making and psychological flexibility. Preliminary observations from clinical practice and brief case examples illustrate possible processes of change beyond symptom reduction.
Susanne Prinz is a psychiatrist, psychotherapist and senior physician at the Psychiatric University Hospital Zurich. Her clinical and research work includes psychedelic-assisted therapy and its implementation in psychiatric care.
Difficulties following naturalistic psychedelic use and associations with adverse childhood experiencesMichelle Olofsson · 1 h 3 minWhat difficulties can follow psychedelic use outside clinical trials, and who may be more vulnerable? Michelle Olofsson presents survey research on the types, frequency and duration of reported difficulties. She then examines adverse childhood experiences as a possible risk factor and considers implications for harm reduction and research safety.
Michelle Olofsson is a doctoral researcher in the NIH–Karolinska Institutet Graduate Partnership Program. Her work examines psychedelic effects, risks and therapeutic potential in populations with histories of trauma and early-life stress.
Clinical Pharmacology of Classical PsychedelicsFriederike Holze · 59 minHow do classic psychedelics and entactogens differ, and why do those differences matter for clinical research? Friederike Holze compares substances including LSD, psilocybin, DMT, mescaline and MDMA. The talk examines dosing, pharmacokinetics, drug interactions and acute effects, while considering the implications for individualized treatment.
Friederike Holze leads clinical research in the Division of Clinical Pharmacology and Toxicology at University Hospital Basel. Her controlled studies investigate the pharmacokinetics and acute effects of psychedelics and entactogens, including LSD, psilocybin and MDMA.
Therapeutic Relevance of Psychedelic ExperiencesNathan Strebel · 1 h 1 minHow much does the psychedelic experience itself matter in therapy? Nathan Strebel examines the debate between neurobiological explanations and the possible therapeutic importance of subjective experience. He presents a patient survey asking which aspects of psychedelic-assisted therapy participants considered valuable, bringing their perspectives into a discussion often led by researchers and clinicians.
Nathan Strebel is a psychologist and psychotherapist in training whose research examines patients’ perspectives on the therapeutic value of psychedelic experiences.
Speaker source ↗
Neurobehavioral and Molecular Pharmacology of DMT and HarmineKlemens Egger · 59 minKlemens Egger introduces the pharmacology of DMT and harmine, the compounds used in ayahuasca-inspired formulations sometimes called pharmahuasca. The talk considers how these substances act in the brain and why their interactions are being investigated in psychedelic research.
Klemens Egger is a neuroscientist whose work at the University of Zurich investigates DMT and harmine, from their pharmacological interactions to their effects on human brain activity. His background spans chemistry and biomedical neuroscience.
Speaker source ↗
Psychedelics and PsychotherapyGregor Hasler · 1 hWhat does psychotherapy contribute to psychedelic treatment? Gregor Hasler discusses guided sessions, emotional processing and the role of a safe therapeutic setting. The lecture introduces the Helioscope Effect alongside neuroplasticity and the REBUS framework, while considering questions about dose, safety and longer-term outcomes.
Gregor Hasler is a psychiatrist, psychotherapist and neuroscientist at the University of Fribourg. His research uses brain imaging to investigate stress-related psychiatric disorders, including depression, and approaches to their treatment.
Speaker source ↗
Psychedelics and Terminal Illness: A Patient’s PerspectiveAndrea Siclari · 1 h 6 minAndrea Siclari offers a patient’s perspective on LSD-assisted therapy while living with a life-threatening illness. He describes changes in his relationship to illness, family and his own life, including experiences of connection and emotional insight. His account concerns living with illness and finding meaning; it is a personal testimony, not evidence that psychedelics treat cancer.
Andrea Siclari participated in a Swiss study of LSD-assisted therapy for people with life-threatening illnesses. He shares his experience publicly to bring patients’ perspectives into conversations about psychedelic care.
The Role of Psychotherapy in Psychedelic Research and TreatmentJohannes Jungwirth · 56 minIs psychotherapy an essential part of psychedelic treatment, or can psychological support be enough? Johannes Jungwirth examines how these approaches differ, what the research can tell us, and which questions remain unresolved. The talk focuses on the role of therapeutic work in both clinical studies and treatment.
Johannes Jungwirth is a senior physician in adult psychiatry and psychotherapy at the Psychiatric University Hospital Zurich. His clinical and research work includes psilocybin-assisted treatment for depression.
Speaker source ↗
Gestalt Therapy in Psychedelic-Assisted PsychotherapyStephan Fundinger · 1 h 6 minStephan Fundinger explores how Gestalt therapy can inform psychedelic-assisted psychotherapy and integration. He connects its emphasis on present-moment awareness, embodied experience and relationships with work during and after psychedelic sessions. A clinical example involving MDMA illustrates how these principles can shape the therapeutic process.
Stephan Fundinger is a psychologist who works with Gestalt therapy and psychedelic-assisted psychotherapy. In this lecture, he brings a clinical perspective to the relationship between therapeutic practice and psychedelic integration.
Psychedelics and NeuroplasticityMorten Lietz · 1 h 2 minMorten Lietz examines the different meanings and scales of neuroplasticity, and how researchers can measure changes associated with psychedelics. The talk weighs their possible therapeutic relevance and introduces research investigating whether neuroplasticity-enhancing substances can support cognitive training.
Morten Lietz is a doctoral researcher in medical science at the University of Fribourg. He studies LSD and neuroplasticity across the lifespan, combining measures of cognition, brain physiology, subjective experience and safety.
Speaker source ↗
Psilocybin and Depression: Insights from a Randomized Clinical TrialRobin von Rotz · 1 h 3 minRobin von Rotz discusses a randomized clinical trial of psilocybin for depression and the challenges of developing psychedelic treatments. Topics include set and setting, blinding, nocebo effects and the ethical questions these raise. The lecture also considers what the study may suggest for group therapy and more individualized approaches to care.
Robin von Rotz is a psychologist working in psychopharmacology at the University of Zurich. His research combines clinical and neuroimaging approaches to investigate psilocybin, emotion regulation and self-related processes in depression.
Speaker source ↗
The Neurochemistry of DMTPaul Cumming · 1 h 6 minPaul Cumming introduces the neurochemistry of DMT and the beta-carboline compounds found in ayahuasca, including harmine, harmaline and tetrahydroharmine. The lecture places these substances in the context of neurotransmitter research and the study of psychedelic effects in the brain.
Paul Cumming is a neuroscientist whose work uses molecular imaging, including positron emission tomography, to study neurotransmitter systems. His research spans psychiatric and neurodegenerative disorders as well as psychedelics and monoamine oxidase inhibitors.
Psychedelic Ego-DissolutionJason K. Day · 1 h 5 minWhat does “ego-dissolution” actually describe? Drawing on a qualitative analysis of more than 1,500 experience reports, Jason K. Day distinguishes several forms of altered self-awareness. The talk questions whether these experiences support the stronger claim that consciousness can occur without any self-awareness at all.
Jason K. Day is a philosopher at the University of Fribourg specializing in psychedelics, phenomenology and aesthetics. Their work examines attention and the structure of psychedelic experience.
Speaker source ↗
DMT and Brain Activity in Naturalistic and Clinical SettingsVictoria Joris · 41 minVictoria Joris presents research on DMT use in a naturalistic setting at Boom Festival, conducted with Christopher Timmermann and colleagues. Combining preliminary EEG and questionnaire data, the talk considers how brain recordings and reports of lived experience can inform each other in the study of consciousness.
Victoria Joris has worked with Christopher Timmermann’s research team on DMT and brain activity in naturalistic settings. The work presented here combines EEG recordings with participants’ accounts of their experiences.
Neuroplasticity and Psychedelics: From Molecular Mechanisms to Applied InterventionsMorten Lietz · 45 minHow can changes in neuroplasticity be connected to useful interventions? Morten Lietz surveys the effects of psychedelics across different levels of brain organization and the methods used to assess them. He then discusses research exploring whether psychoplastogens can enhance the effects of cognitive training.
Morten Lietz is a doctoral researcher in medical science at the University of Fribourg. He studies LSD and neuroplasticity across the lifespan, combining measures of cognition, brain physiology, subjective experience and safety.
Speaker source ↗
Behaviour and Neural Activity Across Doses of LSD in MiceGabrielle Michon · 45 minGabrielle Michon presents a preclinical study examining how different doses of LSD affect behaviour and neural activity in mice. The work addresses inconsistent dosing across animal studies and seeks to map dose-dependent responses more systematically. These are animal findings, providing a basis for further research rather than direct conclusions about treatment in humans.
Gabrielle Michon presented this work at the ALPS Student Forum in Zurich. Her presentation focuses on preclinical research linking LSD dose, behaviour and neural activity in mice.
Could Microdosing Cause Fibrosis?Antonin Rouaud · 45 minCould repeated psychedelic microdosing carry risks for heart tissue? Antonin Rouaud examines concerns about stimulation of the serotonin 5-HT2B receptor and its association with fibrosis, drawing comparisons with known cardiotoxic substances. The talk identifies a safety question requiring further research rather than establishing the risk of a particular microdosing regimen.
Antonin Rouaud co-authored research reviewing microdosing, cardiac fibrosis and valvular disease with Abigail Calder and Gregor Hasler. He presented this topic at the 2024 ALPS Student Forum hosted with PROZ.
Speaker source ↗
Are Psychedelic-Induced Mystical States Metacognitive Feelings?Megan Geyer · 38 minMegan Geyer considers whether psychedelic-induced mystical states can be understood through metacognitive feelings: the feelings through which we evaluate our own thinking and knowing. Presenting her master’s research, she connects questions about altered consciousness with the study of metacognition.
Megan Geyer presented this research as a master’s student in psychology at the ALPS Student Conference in Zurich. Her thesis explored metacognitive feelings in relation to psychedelic experience.
The Subjective and Pharmacological Effects of 1P-LSDVolker Auwärter · 1 h 2 minVolker Auwärter discusses the subjective and pharmacological effects of 1P-LSD, drawing on a self-administration study. The lecture approaches this LSD-related substance through toxicology and the investigation of new psychoactive compounds.
Volker Auwärter is a toxicologist who studies new psychoactive substances. His work includes identifying synthetic cannabinoids and investigating the pharmacology of compounds such as 1P-LSD.
The Psychedelic SpectrumKurt Stocker · 1 h 3 minKurt Stocker explores psychedelic experience as a way of examining consciousness. The lecture brings together questions about subjective experience and psychopharmacology under the theme of the psychedelic spectrum.
Kurt Stocker researches consciousness and psychopharmacology. PROZ’s introduction to this recording describes his work on consciousness studies at ETH Zurich and his research association with University Hospital Basel.
Psychedelics and Cluster HeadachesCyril Petignat and patient speaker · 42 minThis two-part talk begins with the UNIDELIC survey of psychedelic use among Swiss university students, including motivations for use and associations with mindfulness and cognitive flexibility. It then considers research interest in psychedelics for cluster headaches and includes a patient’s personal account of self-treatment. The testimony is presented as lived experience, separate from evidence of clinical efficacy.
Cyril Petignat trained in psychology and neuroscience and combines interests in clinical practice, altered states and research. In this recording, he is joined by a patient speaker sharing a personal experience of cluster headaches.
Speaker source ↗
The Effects of Psilocybin on Brain EntropyDrummond McCulloch · 50 minWhat is brain entropy, and do different measures describe the same phenomenon? Drummond McCulloch examines research on acute psilocybin effects in brain imaging, where studies have often used distinct metrics. He explains the challenge of comparing those measures and the case for testing and integrating them across independent datasets.
Drummond McCulloch trained in pharmacology and neuroscience at the University of Glasgow and pursued doctoral research at the University of Copenhagen. His research focuses on understanding psychedelic effects and improving treatment approaches.
Psychedelics and Neuroplasticity: Not from Drugs Alone?Abigail Calder · 1 h 2 minAnimal research suggests that psychedelics can enhance neuroplasticity, but how well does this translate to people? Abigail Calder examines the influence of experience, environment and behaviour on plasticity. The talk asks what may be missed when therapeutic change is explained as a drug effect alone.
Abigail Calder researches the effects of psychedelics on measures of neuroplasticity in humans. Her doctoral work at the University of Fribourg examined this question within medical science.
Speaker source ↗
Ayahuasca and Ayahuasca-Inspired FormulationsHelena Aicher · 1 h 12 minHelena Aicher introduces ayahuasca research at the University of Zurich and work with ayahuasca-inspired formulations. The talk connects the study of subjective experience with questions about relationships, psychotherapy and the contexts in which psychedelic experiences take place.
Helena Aicher is an analytical psychotherapist and researcher studying serotonergic psychoactive compounds, particularly ayahuasca. Her work considers subjective experience, relationships and the contribution of psychotherapy and context to psychedelic-assisted therapy.
Beyond the High: Investigating the Long-Term Effects of MDMANicole Friedli · 55 minNicole Friedli discusses the question of MDMA’s longer-term effects on the brain through research conducted for her master’s thesis. Using diffusion tensor imaging, the work examines brain structure in relation to MDMA use and contributes to the debate about possible neurotoxicity.
Nicole Friedli studied psychology and biology at the University of Zurich and completed a master’s degree. Her research investigated psychoactive substances, including MDMA; she subsequently joined SRF’s science editorial team.
Speaker source ↗Student-led. Open to everyone.
We are a student association exploring psychedelics through science and philosophy. Together, we make space for informed, open discussion of their potential, risks, and place in society.
